Medulloblastoma, Primitive Neuroectodermal Tumors, and Pineal Tumors

Sandberg, Avery A.; Stone, John F.

doi:10.1007/978-1-59745-510-7_8

Cited by 3 publications

(2 citation statements)

References 739 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The negative effects are: (1) low permeability of blood-brain barrier to cytostatics [ 35 , 36 ], (2) low selectivity of courses, (3) open questions in terms of the mechanisms of drug action, making it difficult to estimate the number of molecules interacting with a tumor [ 37 ], (4) enhanced toxic effect of courses, leading to destruction of intact cells together with tumor cells and destruction of the immune system [ 36 , 38 , 39 ].…”

Section: Resultsmentioning

confidence: 99%

Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier

et al. 2011

View full text Add to dashboard Cite

Research concerning new targeting delivery systems for pharmacologically active molecules and genetic material is of great importance. The aim of the present study was to investigate the potential of fourth generation (P4) cationic phosphorus-containing dendrimers to bind fluorescent probe 8-anilino-1-naphthalenesulfonate (ANS), anti-neoplastic drug cisplatin, anti-HIV siRNA siP24 and its capability to deliver green fluorescent protein gene (pGFP) into cells. The interaction between P4 and ANS (as the model drug) was investigated. The binding constant and the number of binding centers per one molecule of P4 were determined. In addition, the dendriplex between P4 and anti-HIV siRNA siP24 was characterized using circular dichroism, fluorescence polarization and zeta-potential methods; the average hydrodynamic diameter of the dendriplex was calculated using zeta-size measurements. The efficiency of transfection of pGFP using P4 was determined in HEK293 cells and human mesenchymal stem cells, and the cytotoxicity of the P4-pGFP dendriplex was studied. Furthermore, enhancement of the toxic action of the anti-neoplastic drug cisplatin by P4 dendrimers was estimated. Based on the results, the fourth generation cationic phosphorus-containing dendrimers seem to be a good drug and gene delivery carrier candidate.

show abstract

Section: Resultsmentioning

confidence: 99%

Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Peripheral nerve sheath tumors (PNSTs) are relatively common, occurring in ∼ 40 of 100,000 individuals. 24 25 26 27 They occur in benign (BPNST) and malignant (MPNST) forms and occur both sporadically (nonsyndromic) and in association with neurogenetic conditions (syndromic), including neurofibromatosis type 1 (NF1), NF2, and schwannomatosis. The management of individuals with PNSTs is challenging, and pain is a common and unfortunate experience for those with PNSTs.…”

Section: Case Examplesmentioning

confidence: 99%

A Practical Guide to Sigma-1 Receptor Positron Emission Tomography/Magnetic Resonance Imaging: A New Clinical Molecular Imaging Method to Identify Peripheral Pain Generators in Patients with Chronic Pain

Shen,

Yoon,

Castillo

et al. 2023

Semin Musculoskelet Radiol

View full text Add to dashboard Cite

Accurately identifying the peripheral pain generator in patients with chronic pain remains a major challenge for modern medicine. Millions of patients around the world suffer endlessly from difficult-to-manage debilitating pain because of very limited diagnostic tests and a paucity of pain therapies. To help these patients, we have developed a novel clinical molecular imaging approach, and, in its early stages, it has been shown to accurately identify the exact site of pain generation using an imaging biomarker for the sigma-1 receptor and positron emission tomography/magnetic resonance imaging. We hope the description of the work in this article can help others begin their own pain imaging programs at their respective institutions.

show abstract

The impact of the nerve growth factor on the number of MYCC, MYCN oncogene copies in human medulloblastoma cells

Чернов

2019

Zlokač. opuholi

View full text Add to dashboard Cite

Introduction: The search for new molecular targets for chemotherapy of malignancies, particularly pediatric brain tumors, is a relevant issue of modern oncology. MYC expression and amplification is often observed in brain tumors, which is an unfavorable prognostic factor. Many oncogenic processes are regulated by some growth factors including the nerve growth factor (NGF).Purpose: To study the changes in the number of MYCCand MYCN‑gene copies in MB cells exposed to the NGF.Material and methods: The impact of the NGF on the number of MYCC‑, MYCN oncogene copies in the primary human medulloblastoma cell culture was assessed using the method of fluorescence in situ hybridization.Results: Exposure to the NGF was shown to decrease the number of MB cells containing 6, 8 copies of MYCN oncogenes and 3, 8 copies of MYCC oncogene. The NGF was also shown to increase the number of tumor cells that contain a double set of copies of both oncogenes. There was a statistically significant (p<0.0001) negative correlation (r=–0.65) between the average number of MYCC oncogene copies and the NGF cytotoxicity index.Conclusion: The increased number of oncogene copies reduces the susceptibility of MB cells to the growth factor.

show abstract

Medulloblastoma, Primitive Neuroectodermal Tumors, and Pineal Tumors

Cited by 3 publications

References 739 publications

Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier

Fourth Generation Phosphorus-Containing Dendrimers: Prospective Drug and Gene Delivery Carrier

A Practical Guide to Sigma-1 Receptor Positron Emission Tomography/Magnetic Resonance Imaging: A New Clinical Molecular Imaging Method to Identify Peripheral Pain Generators in Patients with Chronic Pain

The impact of the nerve growth factor on the number of MYCC, MYCN oncogene copies in human medulloblastoma cells

Contact Info

Product

Resources

About